A Form 4 filed on September 16, 2026, discloses that John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 27,400 shares of common stock on September 14, 2026, pursuant to a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: John E. Kao disposed of 27,400 shares of Alignment Healthcare common stock on September 14, 2026.
  • Sale price: The shares were sold at $13 per share, according to the filing.
  • Trading plan: The transaction was made pursuant to a Rule 10b5-1 plan adopted on May 27, 2026.
  • Post-transaction indirect ownership: Following the sale, Kao beneficially owns 590,766 shares indirectly through the JEK Trust, dated February 8, 2021, of which he is the trustee.
  • Direct ownership: Kao also holds 1,223,473 shares of common stock directly following the reported transaction.
  • Roles: The filing identifies Kao as both a Director and Chief Executive Officer of the issuer.

John E. Kao's Share Sale and Beneficial Ownership at Alignment Healthcare

According to the Form 4 filed with the U.S. Securities and Exchange Commission, John E. Kao, Chief Executive Officer and Director of Alignment Healthcare, Inc. (NASDAQ:ALHC), disposed of 27,400 shares of common stock on September 14, 2026, at a price of $13 per share. The filing indicates the transaction was executed under transaction code "S" and was carried out pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The 10b5-1 plan was adopted on May 27, 2026, as noted in the filing's explanation of responses.

The sold shares were held indirectly. Following the transaction, Kao's indirect beneficial ownership stands at 590,766 shares, held through the JEK Trust, dated February 8, 2021, of which the filing states Mr. Kao is the trustee. In addition to his indirect holdings, the filing reports that Kao directly owns 1,223,473 shares of Alignment Healthcare common stock following the reported transaction. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was signed by Christopher J. Joyce, as Attorney-in-Fact for John E. Kao, and dated September 16, 2026. The filing notes the box was checked to indicate the transaction was made pursuant to a Rule 10b5-1(c) plan.

What Was Disclosed

The filing reports a sale of 27,400 shares of Alignment Healthcare common stock by CEO John E. Kao at $13 per share on September 14, 2026, under a pre-adopted 10b5-1 plan. Post-transaction, Kao holds 1,223,473 shares directly and 590,766 shares indirectly via the JEK Trust.